133 related articles for article (PubMed ID: 25944688)
1. Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.
Mock A; Warta R; Geisenberger C; Bischoff R; Schulte A; Lamszus K; Stadler V; Felgenhauer T; Schichor C; Schwartz C; Matschke J; Jungk C; Ahmadi R; Sahm F; Capper D; Glass R; Tonn JC; Westphal M; von Deimling A; Unterberg A; Bermejo JL; Herold-Mende C
Oncotarget; 2015 May; 6(15):13579-90. PubMed ID: 25944688
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival.
Pallasch CP; Struss AK; Munnia A; König J; Steudel WI; Fischer U; Meese E
Int J Cancer; 2005 Nov; 117(3):456-9. PubMed ID: 15906353
[TBL] [Abstract][Full Text] [Related]
3. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.
Struss AK; Romeike BF; Munnia A; Nastainczyk W; Steudel WI; König J; Ohgaki H; Feiden W; Fischer U; Meese E
Oncogene; 2001 Jul; 20(31):4107-14. PubMed ID: 11464277
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
6. Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme.
Zhenjiang L; Rao M; Luo X; Valentini D; von Landenberg A; Meng Q; Sinclair G; Hoffmann N; Karbach J; Altmannsberger HM; Jäger E; Peredo IH; Dodoo E; Maeurer M
EBioMedicine; 2018 Jul; 33():49-56. PubMed ID: 30049387
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.
Geisenberger C; Mock A; Warta R; Rapp C; Schwager C; Korshunov A; Nied AK; Capper D; Brors B; Jungk C; Jones D; Collins VP; Ichimura K; Bäcklund LM; Schnabel E; Mittelbron M; Lahrmann B; Zheng S; Verhaak RG; Grabe N; Pfister SM; Hartmann C; von Deimling A; Debus J; Unterberg A; Abdollahi A; Herold-Mende C
Acta Neuropathol; 2015 Sep; 130(3):419-34. PubMed ID: 25931051
[TBL] [Abstract][Full Text] [Related]
8. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive glioblastoma immunoprofiling by printed peptide arrays.
Mock A; Herold-Mende C
Oncoimmunology; 2016 Feb; 5(2):e1069941. PubMed ID: 27057435
[TBL] [Abstract][Full Text] [Related]
10. Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors.
Barbus S; Tews B; Karra D; Hahn M; Radlwimmer B; Delhomme N; Hartmann C; Felsberg J; Krex D; Schackert G; Martinez R; Reifenberger G; Lichter P
J Natl Cancer Inst; 2011 Apr; 103(7):598-606. PubMed ID: 21346226
[TBL] [Abstract][Full Text] [Related]
11. Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis.
Hecker M; Lorenz P; Steinbeck F; Hong L; Riemekasten G; Li Y; Zettl UK; Thiesen HJ
Autoimmun Rev; 2012 Jan; 11(3):180-90. PubMed ID: 21621003
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
14. Markers of cell division cycle in glioblastoma: significance in prediction of treatment response and patient prognosis.
Yousaf J; Hills C; Dixit S; Achawal S; O'Brien D; Greenman J; Scott IS
Br J Neurosurg; 2013 Dec; 27(6):752-8. PubMed ID: 23477614
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
Odrazka K; Petera J; Kohlova T; Dolezel M; Vaculikova M; Zouhar M; Malek V; Hobza V; Latr I; Nemecek S; Sercl M; Ryska P; Blaha M; Cermakova E
Strahlenther Onkol; 2003 Sep; 179(9):615-9. PubMed ID: 14628127
[TBL] [Abstract][Full Text] [Related]
17. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients.
Carlsson A; Persson O; Ingvarsson J; Widegren B; Salford L; Borrebaeck CA; Wingren C
Proteomics Clin Appl; 2010 Jul; 4(6-7):591-602. PubMed ID: 21137077
[TBL] [Abstract][Full Text] [Related]
18. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
Del Vecchio CA; Wong AJ
Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma multiforme with long term survival.
Deb P; Sharma MC; Mahapatra AK; Agarwal D; Sarkar C
Neurol India; 2005 Sep; 53(3):329-32. PubMed ID: 16230803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
